乳腺癌患者内分泌治疗服药监控平台的设计及应用

发布时间：2017-12-27 00:28

本文关键词：乳腺癌患者内分泌治疗服药监控平台的设计及应用　出处：《中华护理杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的探索基于乳腺癌内分泌服药监控平台的护士随访对接受内分泌治疗的乳腺癌患者服药依从性和生活质量的影响。方法构建针对内分泌治疗乳腺癌患者的服药监控平台,采用随机对照研究设计,患者被随机分为实验组157例和对照组154例。实验组在常规护理的基础上,实施基于药物监控平台的护士随访。对照组采用常规随访模式,参加医院的门诊常规随访。分别评价两组在3个月、6个月、18个月和24个月的服药依从性和生活质量。结果实验组的服药依从性评分分别在6个月、18个月、24个月较对照组显著提高(P0.05),生活质量问卷各个维度存在显著的时间效应,但不具有组间差异(P0.05)。结论基于药物监控平台的护士随访可提高内分泌治疗的乳腺癌患者的服药依从性,但对改善总体生活质量效果不明显。
[Abstract]:Objective to explore the effect of nurse follow-up on endocrine compliance and quality of life in patients with breast cancer receiving endocrine therapy. Methods a drug monitoring platform for breast cancer patients with endocrine therapy was established. A randomized controlled study was designed. The patients were randomly divided into experimental group (157 cases) and control group (154 cases). On the basis of routine nursing, the experimental group carried out the follow-up of nurses based on the drug monitoring platform. The control group was followed up by routine follow-up. The compliance and quality of life of the two groups were evaluated in 3, 6, 18 and 24 months respectively. Results the scores of medication adherence in the experimental group were significantly higher than those in the control group at 6 months, 18 months, 24 months (P0.05). There was significant time effect in all dimensions of the quality of life questionnaire, but there was no difference between the two groups (P0.05). Conclusion nurse follow-up based on drug monitoring platform can improve the medication adherence of endocrine therapy breast cancer patients, but it has no obvious effect on improving the overall quality of life.
【作者单位】：复旦大学护理学院;复旦大学附属肿瘤医院乳腺外科;复旦大学附属肿瘤医院护理部;
【基金】：上海市卫生局局级科研项目(KBF400803)
【分类号】：R473.73
【正文快照】： 乳腺癌是女性最常见的肿瘤,占我国所有女性癌的15%,并且发病率呈逐年上升的趋势[1]。内分泌治疗是乳腺癌主要全身治疗手段之一。2012年美国国家综合癌症网络(National Comprehensive CancerNetwork,NCCN)乳腺癌临床实践指南[2]建议,雌激素受体和(或)孕激素受体表达阳性的乳腺

【参考文献】